SVB Securities analyst Marc Goodman reiterated a Buy rating on Opthea Limited Sponsored ADR (OPT – Research Report) on October 7 and set a price target of $25.00. The company’s shares closed last Monday at $5.24.
Goodman covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Biogen, and Aldeyra Therapeutics. According to TipRanks, Goodman has an average return of 1.2% and a 44.71% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Opthea Limited Sponsored ADR.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $8.50 and a one-year low of $4.73. Currently, Opthea Limited Sponsored ADR has an average volume of 3,499.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea’s development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
Read More on OPT:
- Opthea price target lowered to $44 from $45 at Citi
- Opthea Reports Fiscal Year 2022 Financial Results and Corporate Highlights
- Opthea Announces Presentation at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
- Opthea Secures up to US$170 Million in Non-Dilutive Financing for OPT-302 in wet AMD
- Opthea Successfully Closes Well Supported US$90 Million Equity Financing
